Skip to main content
Log in

CD44 exon 6 expression as a possible early prognostic factor in primary node negative breast carcinoma

  • Research papers
  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Breast cancer is the most common female malignancy affecting approximately one woman in eight. Many attempts have been made to define markers which may have potential clinical applications in diagnosis as well as therapy. New isoforms of CD44 with alternative spliced exons have recently been described. We studied the expression of CD44 exon 6 using a semi-quantitative RT-PCR reaction on a panel of 25 normal breast specimens, 10 mammary fibroadenomas, eight cystic samples and 52 primary breast tumors. Significant correlation was found between CD44 exon 6 expression and the overall survival of the N-M-population,P = 0.032, (logrank test by Mantel's method). The same result was also observed for the disease-free survival,P = 0.000002 (logrank test by Mantel's method). CD44 exon 6 expression, as detected by our RT-PCR-based method, might be a useful prognostic indicator of metastasis in breast cancer. However, these preliminary results need to be confirmed by later retrospective and prospective studies on a larger number of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Berg EL, Haynes B, Goldstein LA,et al. 1989, Homing receptors and vascular addressins: cell adhesion molecules that direct lymphocyte traffic.Immunol Rev,108, 5–18.

    Google Scholar 

  2. Fox SB, Gatter KC, Jackson DG,et al. 1993, CD44 and cancer screening.Lancet,342, 548–9.

    Google Scholar 

  3. Jalkanen S, Bargatze RF, Herron LR and Butcher EC, 1986, A lymphoid cell surface protein involved in endothelial cell recognition and lymphocyte homing in man.Eur J Immunol,16, 1195–202.

    Google Scholar 

  4. Aruffo A, Stamenkovic I, Melnick M, Underhill CB and Seed B, 1990, CD44 is the principal cell surface receptor for hyaluronate.Cell,61, 1303–13.

    Google Scholar 

  5. Sy MS, Guo YJ and Stamenkovic I, 1991, Distinct effects of two CD44 isoforms on tumor growthin vivo.J Exp Med,174, 859–66.

    Google Scholar 

  6. Günthert U, Hofmann M, Rudy W,et al. 1991, A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells.Cell,65, 13–24.

    Google Scholar 

  7. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U and Bell JI, 1992, Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons.Proc Natl Acad Sci,89, 12160–4.

    Google Scholar 

  8. Seiter S, Arch R, Reber S,et al. 1993, Prevention of tumor metastasis formation by anti-variant CD44.J Exp Med,177, 443–55.

    Google Scholar 

  9. Labarriere N, Piau JP, Otry C,et al. 1994, H blood group antigen carried by CD44v modulates tumorigenicity of rat colon carcinoma cells.Cancer Res,54, 6275–81.

    Google Scholar 

  10. Finke LH, Terpe HJ, Zörb C, Haensch W and Schlag PM, 1995, Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins.Lancet,345, 583–4.

    Google Scholar 

  11. Ichikawa W, 1994, Positive relationship between expression of CD44 and hepatic metastases in colorectal cancer.Pathobiology,62, 172–9.

    Google Scholar 

  12. Tanabe KK, Ellis LM and Saya H, 1993, Expression of CD44R1 adhesion molecule in colon carcinomas and metastases.Lancet,341, 725–6.

    Google Scholar 

  13. Washington K, Gottfried MR and Telen MJ, 1994, Expression of the cell adhesion molecule CD44 in gastric adenocarcinomas.Human Pathol,25, 1043–9.

    Google Scholar 

  14. Heider KH, Dämmrich J, Skroch-Angel P,et al. 1993, Differential expression of CD44 splice variants in intestinal and diffuse type human gastric carcinomas and normal gastric mucosa.Cancer Res,53, 4197–203.

    Google Scholar 

  15. Takada M, Yamamoto M and Saitoh Y, 1993, The significance of CD44 in human pancreatic cancer: high expression of CD44 in human pancreatic adenocarcinoma.Pancreas,9, 748–52.

    Google Scholar 

  16. Takada M, Yamamoto M and Saitoh Y, 1993, The significance of CD44 in human pancreatic cancer: the role of CD44 in human pancreatic adenocarcinoma invasion.Pancreas,9, 753–7.

    Google Scholar 

  17. Washimi O, Ueda R, Ariyoshi Y,et al. 1994, Expression of CD44 variant isoforms in normal and neoplastic cells of the lung.Jpn J Cancer Res,85, 1112–16.

    Google Scholar 

  18. Penno MB, August TA, Baylin SB,et al. 1994, Expression of CD44 in human lung tumors.Cancer Res,54, 1381–7.

    Google Scholar 

  19. Morimoto K, Le Bousse-Kerdiles MC, Li Y, Jasmin C and Smadja-Joffe F, 1994, CD44 mediates hyaluronan binding by human myeloid KG1A and KG1 cells.Blood,83, 657–62.

    Google Scholar 

  20. Salles G, Zain M, Jiang W, Boussiotis V and Shipp M, 1993, Alternatively spliced CD44 transcripts in diffuse large-cell lymphomas: characterization and comparison with normal activated B cells and epithelial malignancies.Blood,82, 3539–47.

    Google Scholar 

  21. Terpe HJ, Koopmann R, Imhof BA and Günthert U, 1994, Expression of integrins and CD44 isoforms in non-Hodgkin's lymphomas: CD44 variant isoforms are preferentially expressed in high-grade malignant lymphomas.J Pathol,174, 89–100.

    Google Scholar 

  22. Dougherty GJ, Lansdorp PM, Cooper DL and Humphries RK, 1991, Molecular cloning of CD44R1 and CD44R2, two novel isoforms of the human CD44 lymphocyte ‘homing’ receptor expressed by hemopoietic cells.J Exp Med,174, 1–5.

    Google Scholar 

  23. Brown TA, Bouchard T, St John T, Wayner E and Carter WG, 1991, Human keratinocytes express a new CD44 core protein (CD44E) as a heparan-sulfate intrinsic membrane proteoglycan with additional exons.J Cell Biol,113, 207–21.

    Google Scholar 

  24. Cannistra SA, Kansas GS, Niloff J, De Franzo B, Kim Y and Ottensmeier C, 1993, Binding of ovarian cancer cells to peritoneal mesotheliumin vitro is partly mediated by CD44H.Cancer Res,53, 3830–8.

    Google Scholar 

  25. Birch M, Mitchell S and Hart IR, 1991, Isolation and characterization of human melanoma cell variants expressing high and low levels of CD44.Cancer Res,51, 6660–7.

    Google Scholar 

  26. Kuppner MC, Van Meier E, Gauthier T, Hamou MF and De Tribolet N, 1992, Differential expression of the CD44 molecule in human brain tumors.Int J Cancer,50, 572–7.

    Google Scholar 

  27. Asplund T and Heldin P, 1994, Hyaluronan receptors are expressed on human mesothelioma cells but not on normal mesothelial cells.Cancer Res,54, 4516–23.

    Google Scholar 

  28. Behzad F, Seif MW, Campbell S and Aplin JD, 1991, Expression of two isoforms of CD44 in human endometrium.Biol Reprod,51, 739–47.

    Google Scholar 

  29. Fox SB, Fawcett J, Jackson DG,et al. 1994, Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms.Cancer Res,54, 4539–46.

    Google Scholar 

  30. Kaufmann M, Heider KH, Sinn HP, von Minckwitz G, Ponta H and Herrlich P, 1995, CD44 variant exon epitopes in primary breast cancer and length of survival.Lancet,345, 615–19.

    Google Scholar 

  31. Matsumara Y and Tarin D, 1992, Significance of CD44 gene products for cancer diagnosis and disease evaluation.Lancet,340, 1053–8.

    Google Scholar 

  32. Dall P, Heider KH, Sinn HP,et al. 1995, Comparison of immunohistochemistry and RT-PCR for detection of CD44v-expression, a new prognostic factor in human breast cancer.Int J Cancer, 60, 471–7.

    Google Scholar 

  33. Iida N and Bourguignon LYW, 1995, New CD44 splice variants associated with human breast cancers.J Cell Physiol,162, 127–33.

    Google Scholar 

  34. Günthert U, Stauder R, Mayer B, Terpe HJ, Finke L and Friedrichs K, 1995, Are CD44 isoforms involved in human tumor progression?Cancer Surv,214, 19–42.

    Google Scholar 

  35. Ruiz P, Schwärzler C and Günthert, 1995, CD44 isoforms during differentiation and development.Bioessays,17, 17–24.

    Google Scholar 

  36. International Union Against Cancer (UICC), 1987. TNM Classification of Malignant Tumors, 4th edn. Berlin: Springer-Verlag, pp. 748–59.

    Google Scholar 

  37. Hartmann WH, Uzello L, Sobin LH and Stalsberg H (eds), 1981.Histological Typing of Breast Tumors, 2nd edition. Geneva: World Health Organization, pp. 15–25.

    Google Scholar 

  38. Bloom HJG and Richardson WW, 1957, Histological grading and prognosis in breast cancer.Br J Cancer,11,359–77.

    Google Scholar 

  39. Rio MC, Bellocq JP, Gairard B,et al. 1987, Specific expression of the pS2 gene in subclasses of breast cancers in comparison with expression of the oestrogen and progesterone receptors and the oncogene ERBB2.Proc Natl Acad Sci,84, 9243–7.

    Google Scholar 

  40. Chomczynski P and Sacchi N, 1987, Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction.Analyt Biochem,162, 156–9.

    Google Scholar 

  41. Kaplan EL and Meier P, 1958, Non parametric estimation from incomplete observations.J Am Stat Assoc, 53, 457–81.

    Google Scholar 

  42. Peto R, Pike MC and Armitage P, 1977, Design and analysis of randomized clinical trials requiring prolonged observations of each patient.Br J Cancer,35, 1–39.

    Google Scholar 

  43. Kaufmann M, Heider K-H, Sinn H-P, von Minckwitz G, Ponta H and Herrlich P, 1995, CD44 isoforms in prognosis of breast cancer.Lancet,346, 502.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Guriec, N., Guriec, L., Gairard, B. et al. CD44 exon 6 expression as a possible early prognostic factor in primary node negative breast carcinoma. Clin Exp Metast 14, 434–439 (1996). https://doi.org/10.1007/BF00128959

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00128959

Keywords

Navigation